Lycopene is the red carotenoid pigment in tomatoes and watermelon, and the most potent singlet oxygen quencher among all dietary carotenoids — 2x more potent than beta-carotene. Our research shows the strongest evidence for prostate cancer risk reduction: a meta-analysis of 26 studies found men in the highest lycopene intake quintile had a 26% lower risk of prostate cancer. Cooked tomato products (sauce, paste) provide dramatically better bioavailability than raw tomatoes due to heat-released trans-to-cis isomerization.
Lycopene's primary mechanism is singlet oxygen quenching — it neutralizes one of the most reactive free radical species in biological systems. In the prostate, lycopene concentrates at 3-10x plasma levels (active uptake) where it: (1) inhibits IGF-1 signaling (growth factor implicated in prostate cancer progression); (2) activates phase II detoxification enzymes; (3) inhibits NF-κB inflammatory signaling; and (4) reduces androgen receptor signaling. For cardiovascular protection, it prevents LDL oxidation (the initiating step in atherosclerosis) and improves endothelial function.
No significant drug interactions have been identified in clinical literature. Lycopene is a naturally occurring carotenoid with no known pharmacological interactions. As a fat-soluble compound, malabsorption conditions or drugs that impair fat absorption (orlistat) may reduce lycopene uptake.
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.